LUPAS is an acronym for Luminescent Polymers for in vivo imaging of Amyloid Signatures and it is an EU project within the Seventh Framework Programme. The goal with the LUPAS project is to develop novel tools for diagnosis and therapy for Alzheimer disease and prion diseases.
LUPAS project seeks to bridge the gap between diagnosis and treatment of Alzheimer disease and prion diseases. By developing novel agents and methods for diagnostic imaging of amyloid plaque it is possible to improve quality of diagnosis as well as facilitate monitoring and understanding of the disease progression.
The novel imaging tools or reporter molecules are based on luminescent conjugated polymers.LCPs. It is known that these molecules can bind effectively to amyloid plaques and when they bind their molecular structure is altered and this alteration causes the protein to respond optically in very specific way – like an optical fingerprint, which can be readily recognised. Moreover, these molecular scaffolds will be evaluated as template pharmacophores for prevention of protein aggregation and could possibly facilitate treatment of AD and prionoses.
Members of the LUPAS consortium:
The LUPAS project
LCP staining of protein deposits in brain tissue from transgenic mouse models for AD and prion diseases.
a) Brain tissue from an age matched control mouse.
b) Brain tissue from a mouse with AD-like pathology. The LCP stained protein plaque deposits are clearly seen in green colour.
c) Brain tissue from a mouse infected with a distinct prion strain. The LCP stained prion deposits are seen in yellow-red colour.
Click here to read the full report.
For more information, contact us.